REYON Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
July 06, 2018 at 10:13 am IST
Share
REYON Pharmaceutical Co., Ltd. (KOSE:A102460) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Daewoo Securities Co. Ltd. The purpose of the share repurchase program is to stabilize the share price and improve the shareholders value. The share repurchase program is valid until January 5, 2019. As of July 5, 2018, the company had no shares in treasury within scope available for dividend and had 1,285 shares in treasury through other repurchase.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 